Peter Bojko

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.

M. E. Scheulen, Ralf A. Hilger, C. Oberhoff et al. · PubMed · 2000 · 110 citations

Cell Therapy, Pathology, Pharmacotherapy +18

Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution

Simon Mller, P. Sch�tt, Peter Bojko et al. · Annals of Hematology · 2004 · 65 citations

Urology, Chronic Kidney Disease, Hematology +5

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma

Philipp Schütt, Peter R. Ebeling, Ulrike Buttkereit et al. · European Journal Of Haematology · 2004 · 46 citations

Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients

Mohammad R. Nowrousian, S. R. Waschke, Peter Bojko et al. · Annals of Oncology · 2003 · 35 citations · Full text

Hematological Malignancy, Oncology, Medicine +12